Millions of Patients and Physicians Can Now Access New Treatments and Clinical Trials to Help Slow Disease Progression
CAMBRIDGE, Mass.--(BW HealthWire)--Feb. 14, 2001
Millions afflicted with prostate cancer, stroke, depression, and multiple sclerosis now have access to innovative treatments, clinical trials and expert physician insight through Veritas Medicine. To complement these new offerings, Veritas Medicine has also added four new physician researchers from leading medical centers who provide easy to understand, and highly relevant information about these diseases to help patients and their physicians make the most informed healthcare choices.
Veritas Medicine now provides access to treatments and trials for more than 26 diseases and can be accessed online at www.veritasmedicine.com and via leading health-related non-profit organizations and online sites such as AEGIS, MedicineNet.com, HealthOnline, HepCBC-Hepatitis C Education and Prevention Society, and the Arthritis National Research Foundation.
"Having physician editors from leading medical centers strengthens the reliability and relevancy of our information," said Joe Avellone, M.D., CEO of Veritas Medicine. "Our goal is to have content for over 50 diseases that includes general descriptions of all treatment options for advanced stages of each disease, plus an explanation of all drugs in development and other relevant information to help patients and physicians make decisions about treatment and clinical trial options."
The American Cancer Society estimates that 198,100 men in the United States will be diagnosed with prostate cancer during 2001. Early diagnosis and routine exams are critical factors in increasing the survival rate, as are treatments that are available through clinical trial studies. The Veritas Medicine database includes 86 trials for prostate cancer, information on 20 new treatments, and expert analysis from physician editor Daniel George, M.D., Staff Oncologist, Dana-Farber Cancer Institute; Instructor of Medicine, Harvard Medical School; and Attending Physician, Brigham and Women's Hospital.
"The Internet is potentially a great source of medical information, but it can also obscure and distort important findings for patients and doctors," said Daniel George, M.D. "Veritas Medicine is an authoritative site for patients and physicians in any location, to gain clear and concise reviews of the best treatments, in a format that is useful for decision making."
David Thaler, M.D., Co-Director, Tufts Comprehensive Stroke Center at the New England Medical Center and Assistant Professor, Neurology, Tufts University School of Medicine, joins Veritas Medicine's team to help stroke patients and their physicians understand their treatment options, including the availability of clinical trials for new therapies. He is currently Co-Director at Tufts Comprehensive Stroke Center at the New England Medical Center, Boston, and Assistant Professor of Neurology at Tufts University School of Medicine. Patients, physicians, and family members can gain access to 21 trials and information on 13 new drugs in development for stroke through Veritas Medicine.
Nearly 10 percent of Americans over age 18 are severely depressed in this country, and depression is a leading cause of disability in the U.S. Numerous drugs currently in development can provide potential relief. Veritas Medicine offers information on 7 drugs in development and provides access to 14 different trials throughout the US. Ron Cowan, M.D., Ph.D., Instructor in Psychiatry, Harvard Medical School and Assistant Physiologist, Brain Imaging Center, McLean Hospital, has joined Veritas Medicine as the physician editor for depression.
Thirty-five treatments in development for fighting multiple sclerosis are outlined on the Veritas Medicine website. Michael Panzara, M.D., Instructor in Neurology, Harvard Medical School, is the physician researcher for the section of Veritas Medicine devoted to multiple sclerosis.
About Veritas Medicine
Veritas Medicine, based in Cambridge, Massachusetts, is the first comprehensive online medical resource developed to address the needs of patients, physicians and other health care professionals, and pharmaceutical sponsors - all of whom could benefit from a centralized and highly secure online resource that provides expert, reliable and up to date information about clinical trials and innovative treatments. The company is backed by Burrill & Company, BioAsia's Biotechnology Development Fund II and E-Health Holdings Fund, Cambridge Incubator, Seaflower Ventures and MDS Capital.
Contact: Kristy Kozaka/Katherine
The Portico Group